Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone Source: Eur Respir J 2001; 18: 262-268 Year: 2001
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
Maintenance of lung function and asthma control with extrafine beclomethasone/formoterol Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
Treatment of acute severe asthma with formoterol Turbuhaler provides a similar effect on patients' well-being as salbutamol by pMDI plus spacer Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Improved lung function and symptom control with formoterol on demand in asthma Source: Eur Respir J 2006; 27: 504-510 Year: 2006
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
The effectiveness of seretide in children with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004